American Century Companies Inc. Grows Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

American Century Companies Inc. lifted its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 6.0% during the 4th quarter, HoldingsChannel reports. The firm owned 301,087 shares of the company’s stock after buying an additional 17,103 shares during the period. American Century Companies Inc.’s holdings in Takeda Pharmaceutical were worth $3,986,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in Takeda Pharmaceutical in the fourth quarter valued at approximately $26,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Takeda Pharmaceutical during the 3rd quarter valued at $40,000. BNP Paribas Financial Markets raised its position in shares of Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after buying an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC grew its position in Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Cromwell Holdings LLC bought a new position in Takeda Pharmaceutical in the fourth quarter valued at $61,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of Takeda Pharmaceutical stock opened at $14.74 on Friday. The stock has a market capitalization of $46.89 billion, a P/E ratio of 36.84, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The business’s 50 day simple moving average is $14.35 and its two-hundred day simple moving average is $13.93.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.